Pulse Biosciences: nano-PFA reduces benign thyroid nodule volume >50% in feasibility study

PULSE BIOSCIENCES, INC.

First-in-human study (30 patients) shows ≥50% nodule volume reduction and symptomatic relief within 1 month.
Results presented at 2024 American Thyroid Association Annual Meeting by PI Dr. Stefano Spiezia.
No residual fibrosis or scarring observed; potential advantage over thermal ablation and surgery.
Company plans to commence pivotal trial mid-2025 to support U.S. labeling indication.
Study NCT06117085 fully enrolled; long-term follow-up ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.